Niche Pain and Neuro Target preclinical CROs with specialization in neuropathic pain and neurodegenerative diseases, highlighting MD Biosciences Neuro’s GLP-certified lab and advanced readouts to secure collaborations for translational studies.

Expanded Model Portfolio Leverage their pig models and enhanced endpoints such as intraepidermal nerve fiber staining and electrophysiology to propose joint studies that strengthen translational relevance and differentiates from standard rodent-only platforms.

Recent Innovation Position opportunities around the new dry ice stimulation method, presenting it as a cutting-edge assay option that could improve assay sensitivity and cross-validate existing pain and neurodegeneration readouts.

Industry Engagement Capitalize on participation in NeuPSIG 2025 to initiate post-event outreach, offering tailored collaborations, case studies, and co-authored publications to raise visibility and close partnerships with researchers and sponsors.

Growth Opportunity With revenue in the low to mid seven figures and a small-to-mid-size team, pursue scalable CRO partnerships, strategic co-development, and multi-site trials with larger players seeking specialized preclinical neuroscience services.